Printer Friendly

Xytronyx Inc. announces acquisition of exclusive license to novel cancer therapy.

SAN DIEGO--(BUSINESS WIRE)--May 13, 1996--Xytronyx Inc. (ASE: XYX) Monday announced that it has entered into an agreement with Wound Healing of Oklahoma, a privately held corporation ("WHO"), which grants Xytronyx an exclusive worldwide license to WHO's proprietary Laser/Sensitizer Assisted Immunotherapy ("LSAI") technology.

The LSAI technology involves injecting a tumor with an infrared absorbing dye and an immunoadjuvant, followed by treatment with an infrared laser. Similar to traditional Photodynamic Therapy, LSAI is intended to produce tumor tissue destruction in the primary area of treatment. An important distinction of LSAI, however, is that this therapy is also intended to trigger an immune reaction in the patient to complete the destruction of the primary tumor and to destroy metastatic tumors.

Xytronyx expects initially to target breast cancer with the LSAI therapy, although the therapy is also expected to be beneficial in treating lung and prostate cancer. "Our objective is to commence human clinical studies with breast cancer patients before the end of 1996," stated Larry Bymaster, Xytronyx chairman.

Patent applications encompassing the LSAI technology have been filed in the United States and in international markets. The technology was principally developed by two founders of WHO, Dr. Robert Nordquist and Dr. Wei Chen. In conjunction with the license agreement, Xytronyx and WHO have also entered into a research agreement under which WHO will perform further research to assist with the development and commercialization of the technology.

"We are very impressed with the work Dr. Nordquist and Dr. Chen have completed to date," commented Bymaster. "Persuasive results have been achieved with this therapy in conjunction with a very challenging animal tumor model. This technology, and our relationship with WHO, will complement our involvement with Binary Therapeutics Inc. in the photodynamic therapy area."

As previously announced, Xytronyx has entered into a letter of understanding outlining the terms under which it expects to be granted an option to acquire Binary Therapeutics. Xytronyx stated that the final agreement defining the transaction with Binary Therapeutics is nearing completion.

CONTACT: Xytronyx Inc., San Diego

Dale A. Sander/Larry Bymaster, 619/550-3900
COPYRIGHT 1996 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 13, 1996
Previous Article:Barringer Technologies announces first quarter results.
Next Article:Bio-Plexus reports first quarter results; revenues climb 259%.

Related Articles
Xytronyx Inc. announces letter of intent regarding option to purchase Binary Therapeutics Inc.
Xytronyx Inc. announces signing of agreement for option to acquire Binary Therapeutics Inc.
Xytronyx Inc. announces approval of agreement by majority of shareholders of Binary Therapeutics Inc.
Xytronyx Inc. reports fiscal 1997 first-quarter results.
Xytronyx Inc. completes $10 million private placement and announces other significant events.
Xytronyx European partner begins sales of periodontal test.
Development of novel technologies for in vivo imaging. (Fellowships, Grants, & Awards).
Development of novel technologies for in vivo imaging. (Fellowships, Grants & Awards).

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters